Healthcare [ 11/13 ] | Biotechnology [ 94/159 ]
NASDAQ | Common Stock
As of March 21, 2024, Graphite Bio, Inc. was acquired by LENZ Therapeutics, Inc., in a reverse merger transaction.
Graphite Bio, Inc., a clinical-stage gene editing company, engages in developing therapies for serious and life-threatening diseases in the United States.
The company offers GPH102 for the treatment of beta-thalassemia; and GPH201 for the treatment of XSCID, a life-threatening disease for multiple mutations in a single gene.
It also offers GPH301, a product candidate for the treatment of Gaucher disease, a genetic disorder that results in a deficiency in the glucocerebrosidase enzyme.
The company was formerly known as Integral Medicines, Inc., and changed its name to Graphite Bio, Inc. in August 2020.
Graphite Bio, Inc. was incorporated in 2017 and is based in South San Francisco, California.
| Reported Date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 18, 24 | 0 Increased by +100% | -0.13 Increased by +100% |
| Nov 13, 23 | -0.39 Increased by +13.33% | -0.25 Decreased by -56% |
| Aug 14, 23 | -0.97 Decreased by -102.08% | -0.31 Decreased by -212.9% |
| May 11, 23 | -0.43 Increased by +10.42% | -0.33 Decreased by -30.3% |
| Mar 20, 23 | -0.44 Decreased by -25.71% | -0.49 Increased by +10.2% |
| Nov 9, 22 | -0.45 Decreased by -60.71% | -0.46 Increased by +2.17% |
| Aug 11, 22 | -0.48 Increased by +86.09% | -0.49 Increased by +2.04% |
| May 12, 22 | -0.48 Decreased by -41.18% | -0.39 Decreased by -23.08% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 0 Decreased by N/A% | -22.48 M Increased by +3.12% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0 Decreased by N/A% | -55.31 M Decreased by -120.41% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0 Decreased by N/A% | -21.42 M Increased by +16.7% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0 Decreased by N/A% | -22.45 M Decreased by -18.57% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0 Decreased by N/A% | -23.21 M Decreased by -59.06% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 22 | 0 Decreased by N/A% | -25.1 M Decreased by -43.17% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 22 | 0 Decreased by N/A% | -25.71 M Decreased by -30.46% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 21 | 0 Decreased by N/A% | -18.93 M Increased by +70.2% | Decreased by N/A% Decreased by N/A% |